MERCK & Co. has launched its blockbuster cancer immunotherapy Keytruda in India, according to a report in The Economic Times.
Keytruda totalled sales of $1.4b in global revenue last year and the Drug Controller General of India (DCGI) cleared the therapy for use in patients with unresectable or metastatic melanoma.
The above article was sent to subscribers in Pharmacy Daily's issue from 14 Sep 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 14 Sep 17
